Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KT-621 dose-ranging study in uncontrolled moderate to severe eosinophilic asthma
2025-523180-38-00Phase 2Authorised
- Sponsor
- Kymera Therapeutics
- Start
- May 2026
- Modality
- PROTACs (E3 ligase recruitment) → Targeted Protein Degraders (TPDs) → Small Molecules, Bivalent/Multivalent Binders → Multivalent & Scaffold-Based Small Molecules → Small Molecules
- Countries
- 13
01
Overview
Phase 2, randomised, double-blind trial in eosinophilic asthma (EA) comparing KT-621 with Placebo (2 arms). Primary endpoint: Change from baseline to Week 12 in pre-bronchodilator FEV1. Planned start May 2026; status: authorised.
02
Drugs
KT-621
03
Conditions
eosinophilic asthma (EA)
Beyond the preview
Go deeper on 2025-523180-38-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-523180-38-00.